Skip to main content
Premium Trial:

Request an Annual Quote

SGI, Pittsburgh Supercomputing Center, Sigma-Aldrich, Sunset Molecular Discovery, QuantumBio, NIH, RemedyMD, GulfStream Bioinformatics

Premium
PSC Installs ‘Salk’ SGI Altix for Biomedical Research
 
SGI said this week that the Pittsburgh Supercomputing Center has taken delivery of a new Altix 4700 system, called “Salk” for the inventor of the polio vaccine, that will be devoted to biomedical research.
 
PSC acquired the system with support from the National Center for Research Resources. Financial details of the purchase were not disclosed.
 
Salk includes 144 processors and 288 gigabytes of memory.
 

 
Sigma-Aldrich Partners with Sunset Molecular to Expand Gene Search Tool
 
Sigma-Aldrich said this week that it has partnered with Sunset Molecular Discovery to expand data in Sigma’s gene-based search tool, Your Favorite Gene.
 
Sigma said that the collaboration will provide additional information on the functional relationships between bioactive small molecules and genes, and will allow researchers to quickly and easily identify Sigma products that are associated with their genes of interest.
 
Sunset Molecular hosts the chemistry-biology interaction databases Wombat and Wombat-PK, which contain target and bioactivity data.
 
The new information includes more than 3,900 total interactions between bioactive small molecules and their cognate proteins, Sigma said.
 

 
NIH Awards $865K SBIR to QuantumBio to Develop Molecular Modeling Tools
 
QuantumBio said this week that it has been awarded a Small Business Innovation Research grant worth more than $865,000 from the National Institutes of Health to develop molecular modeling software tools.
 
The two-year Phase II SBIR project will focus on developing quantum mechanics-based methods for studying protein/drug interactions. These methods “will ultimately lead to next generation molecular modeling tools used to aid pharmaceutical companies in developing more potent, less expensive drugs and drug-like compounds,” the company said in a statement.
 
In the first phase of the project, the company developed several novel interaction determination methods, which it validated against a number of enzyme targets. The Phase II project will focus on validating these methods with pharmaceutical industry partners, the company said.
 

 
RemedyMD to Integrate GulfStream Bioinformatics' Disease Models with its Research Software
 
RemedyMD and GulfStream Bioinformatics have agreed to integrate their informatics products for translational research, the companies said this week.
 
Under the terms of the agreement, RemedyMD is incorporating GulfStream's 75 disease models into its Investigate data-management platform and is also integrating GulfStream's biospecimen management system, called BIGR, into the Investigate suite.
 
Gary Kennedy, CEO of RemedyMD, said that the combined platform will offer users “a pre-built registry that is already populated with relevant disease-specific data elements, and … a suite of applications and tools to eliminate their data management burdens.”

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.